FDA Approved: RYALTRIS — Original Application (HIKMA SPECIALTY USA INC.)

View source ↗

Summary

FDA approved the original application for RYALTRIS, a fixed-dose nasal spray combining olopatadine HCl and mometasone furoate by Hikma Specialty USA Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)

Snippet

ORIG AP for RYALTRIS (OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE)